AI assistant
Invivyd, Inc. — Director's Dealing 2021
Aug 6, 2021
33564_dirs_2021-08-05_2430d135-0e00-46a7-b869-416dcdcd7640.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Adagio Therapeutics, Inc. (ADGI)
CIK: 0001832038
Period of Report: 2021-08-05
Reporting Person: Dabora Rebecca (Chief Technology Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $0.78 | 2030-09-27 | Common Stock (330880) | Direct | |
| Stock Option (Right to Buy) | $10.14 | 2031-05-06 | Common Stock (569890) | Direct |
Footnotes
F1: One quarter (1/4) of the options shall vest on September 28, 2021, and thereafter, the remainder of the options shall vest in 36 equal monthly installments on the 28th day of each month, subject to the Reporting Person's continuous service on each vesting date.
F2: One quarter (1/4) of the options shall vest on May 7, 2022, and thereafter, the remainder of the options shall vest in 36 equal monthly installments
on the 7th day of each month, subject to the Reporting Person's continuous service on each vesting date.